<?xml version='1.0' encoding='utf-8'?>
<document id="19852077"><sentence text="Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives."><entity charOffset="0-10" id="DDI-PubMed.19852077.s1.e0" text="Irinotecan" /></sentence><sentence text="The introduction of irinotecan has revolutionized the applicability of camptothecins as predominant topoisomerase I inhibitor for anti-cancer therapy"><entity charOffset="20-30" id="DDI-PubMed.19852077.s2.e0" text="irinotecan" /><entity charOffset="71-84" id="DDI-PubMed.19852077.s2.e1" text="camptothecins" /><pair ddi="false" e1="DDI-PubMed.19852077.s2.e0" e2="DDI-PubMed.19852077.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19852077.s2.e0" e2="DDI-PubMed.19852077.s2.e1" /></sentence><sentence text=" The potent anti-tumor activity of irinotecan is due to rapid formation of an in vivo active metabolite, SN-38"><entity charOffset="35-45" id="DDI-PubMed.19852077.s3.e0" text="irinotecan" /></sentence><sentence text=" Therefore, irinotecan is considered as a pro-drug to generate SN-38"><entity charOffset="12-22" id="DDI-PubMed.19852077.s4.e0" text="irinotecan" /></sentence><sentence text=" Over the past decade, side-by-side with the clinical advancement of the use of irinotecan in the oncology field, a plethora of bioanalytical methods have been published to quantify irinotecan, SN-38 and other metabolites"><entity charOffset="80-90" id="DDI-PubMed.19852077.s5.e0" text="irinotecan" /><entity charOffset="182-192" id="DDI-PubMed.19852077.s5.e1" text="irinotecan" /><entity charOffset="194-199" id="DDI-PubMed.19852077.s5.e2" text="SN-38" /><pair ddi="false" e1="DDI-PubMed.19852077.s5.e0" e2="DDI-PubMed.19852077.s5.e0" /><pair ddi="false" e1="DDI-PubMed.19852077.s5.e0" e2="DDI-PubMed.19852077.s5.e1" /><pair ddi="false" e1="DDI-PubMed.19852077.s5.e0" e2="DDI-PubMed.19852077.s5.e2" /><pair ddi="false" e1="DDI-PubMed.19852077.s5.e1" e2="DDI-PubMed.19852077.s5.e1" /><pair ddi="false" e1="DDI-PubMed.19852077.s5.e1" e2="DDI-PubMed.19852077.s5.e2" /></sentence><sentence text=" Because of the availability of HPLC, LC-MS and LC-MS/MS methods, the pharmacokinetic profiling of irinotecan and its metabolites has been accomplished in multiple species, including cancer patients"><entity charOffset="99-109" id="DDI-PubMed.19852077.s6.e0" text="irinotecan" /></sentence><sentence text=" The developed assays continue to find use in the optimization of newly designed delivery systems with regard to pharmacokinetics to promote safe and effective use of either irinotecan or SN-38"><entity charOffset="174-184" id="DDI-PubMed.19852077.s7.e0" text="irinotecan" /><entity charOffset="188-193" id="DDI-PubMed.19852077.s7.e1" text="SN-38" /><pair ddi="false" e1="DDI-PubMed.19852077.s7.e0" e2="DDI-PubMed.19852077.s7.e0" /><pair ddi="false" e1="DDI-PubMed.19852077.s7.e0" e2="DDI-PubMed.19852077.s7.e1" /></sentence><sentence text=" This review intends to: firstly, provide an exhaustive compilation of the published assays for irinotecan, SN-38 and other metabolite(s) of irinotecan, as applicable; secondly, to enumerate the validation parameters and applicable conclusions; and thirdly, provide some recent perspectives in the clinical pharmacology arena pertaining to efflux transporters, pediatric profiling, role of kidney function in defining toxicity, drug-drug interaction potential of irinotecan, etc"><entity charOffset="96-106" id="DDI-PubMed.19852077.s8.e0" text="irinotecan" /><entity charOffset="141-151" id="DDI-PubMed.19852077.s8.e1" text="irinotecan" /><entity charOffset="463-473" id="DDI-PubMed.19852077.s8.e2" text="irinotecan" /><entity charOffset="108-117" id="DDI-PubMed.19852077.s8.e3" text="SN-38" /><pair ddi="false" e1="DDI-PubMed.19852077.s8.e0" e2="DDI-PubMed.19852077.s8.e0" /><pair ddi="false" e1="DDI-PubMed.19852077.s8.e0" e2="DDI-PubMed.19852077.s8.e3" /><pair ddi="false" e1="DDI-PubMed.19852077.s8.e0" e2="DDI-PubMed.19852077.s8.e1" /><pair ddi="false" e1="DDI-PubMed.19852077.s8.e0" e2="DDI-PubMed.19852077.s8.e2" /><pair ddi="false" e1="DDI-PubMed.19852077.s8.e3" e2="DDI-PubMed.19852077.s8.e3" /><pair ddi="false" e1="DDI-PubMed.19852077.s8.e3" e2="DDI-PubMed.19852077.s8.e1" /><pair ddi="false" e1="DDI-PubMed.19852077.s8.e3" e2="DDI-PubMed.19852077.s8.e2" /><pair ddi="false" e1="DDI-PubMed.19852077.s8.e1" e2="DDI-PubMed.19852077.s8.e1" /><pair ddi="false" e1="DDI-PubMed.19852077.s8.e1" e2="DDI-PubMed.19852077.s8.e2" /></sentence><sentence text="" /></document>